NanoCarrier Co., Ltd. (DE:3NQ)
FRANKFURT:3NQ
3NQ Stock Chart & Stats
€0.72
€0.00(0.00%)
At close: 4:00 PM EST
€0.72
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.69 - €1.15
Previous CloseN/A
Volume0.00
Average Volume (3M)772.00
Market Cap
€61.96M
Enterprise Value€9.59B
Total Cash (Recent Filing)€3.40B
Total Debt (Recent Filing)€540.24M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding75,374,160
10 Day Avg. Volume2,257
30 Day Avg. Volume772
Financial Highlights & Ratios
PEG Ratio-1.80
Price to Book (P/B)3.71
Price to Sales (P/S)93.58
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA ~72% gross margin indicates the underlying DDS formulations have strong unit economics and potential for high-margin licensing or manufacturing. Once fixed R&D and SG&A spend are controlled or shifted to partners, this margin supports sustainable profitability and attractive royalties over time.
Manageable LeverageLow and falling leverage increases financial flexibility, lowers refinancing risk, and gives the company runway to pursue development or partnership opportunities without excessive interest burden. This durable improvement supports near-term funding options and strategic choices.
Platform & Partnership Business ModelA platform-focused model centered on nanoparticle DDS and collaborator licensing can generate milestone, service, and future royalty income without single-product commercialization risk. Durable benefit: scalable, potentially non-dilutive revenue streams align incentives with partners and enable capital-efficient growth.
Bears Say
Persistent Cash BurnConsistent negative operating cash flow forces reliance on financing, asset sales, or dilutive capital raises to fund R&D and operations. This structural cash burn limits independent development capacity, increases financing costs or dilution risk, and constrains strategic flexibility over the coming months.
Large Ongoing LossesSevere operating and net losses reflect R&D and overhead far outpacing revenue, eroding equity and investor optionality. Over sustained periods, such losses undermine the balance sheet, reduce bargaining power in partner deals, and make achieving cash-flow breakeven a material structural challenge.
Shrinking Revenue TrendA multi-year decline in revenue weakens operating leverage and reduces the base funding for R&D and commercialization. Falling top-line traction makes it harder to absorb fixed costs, negotiate favorable licenses, and demonstrates limited market adoption of current offerings unless partnerships or new assets reverse the trend.
NanoCarrier Co., Ltd. News
3NQ FAQ
What was NanoCarrier Co., Ltd.’s price range in the past 12 months?
NanoCarrier Co., Ltd. lowest stock price was €0.69 and its highest was €1.15 in the past 12 months.
What is NanoCarrier Co., Ltd.’s market cap?
NanoCarrier Co., Ltd.’s market cap is €61.96M.
When is NanoCarrier Co., Ltd.’s upcoming earnings report date?
NanoCarrier Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 42 days.
How were NanoCarrier Co., Ltd.’s earnings last quarter?
NanoCarrier Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -€0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.015.
Is NanoCarrier Co., Ltd. overvalued?
According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued.
Does NanoCarrier Co., Ltd. pay dividends?
NanoCarrier Co., Ltd. does not currently pay dividends.
What is NanoCarrier Co., Ltd.’s EPS estimate?
NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoCarrier Co., Ltd. have?
NanoCarrier Co., Ltd. has 75,374,160 shares outstanding.
What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?
NanoCarrier Co., Ltd. reported an EPS of -€0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.614%.
Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?
Currently, no hedge funds are holding shares in DE:3NQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NanoCarrier Co., Ltd.
NANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It also engages in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The company was founded by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi on June 14, 1996 and is headquartered in Tokyo, Japan.
Technical Analysis
AnGes
―
OncoTherapy Science
―
Chiome Bioscience Inc.
―
Oncolys BioPharma, Inc.
―
STELLA PHARMA CORPORATION
―